Welcome to our dedicated page for Ibio news (Ticker: IBIO), a resource for investors and traders seeking the latest updates and insights on Ibio stock.
iBio, Inc. (NASDAQ: IBIO) is an AI-driven biotechnology company developing precision antibody therapies for cardiometabolic diseases, obesity, cancer and other hard-to-treat conditions. The IBIO news feed on Stock Titan aggregates company press releases and other coverage so readers can follow how the business and its preclinical pipeline are evolving over time.
Recent news highlights iBio’s focus on obesity and cardiometabolic disease, including preclinical data for its Activin E antibody candidate IBIO-610 and its long-acting anti-myostatin antibody IBIO-600. The company has reported fat-selective, GLP‑1‑synergistic weight loss in diet-induced obesity mouse models, non-human primate pharmacokinetic data suggesting extended half-life and potential for infrequent dosing, and early evidence that its programs may help preserve lean mass in combination with GLP‑1 therapies. Updates also cover presentations at scientific and investor conferences such as ObesityWeek, PEGS Europe and healthcare-focused investment conferences.
Investors tracking IBIO news will also see announcements about financings, including underwritten public offerings, warrant transactions and private placements with institutional investors, along with disclosures on how proceeds are intended to support preclinical cardiometabolic programs and other pipeline assets. Regulatory and corporate developments reported via Form 8‑K, such as Nasdaq listing compliance notices, annual meeting results and updated corporate presentations, provide additional context on governance and capital markets activity.
By following this IBIO news page, readers can monitor new preclinical data, conference participation, financing transactions and key SEC-reported events that shape iBio’s progress as a preclinical-stage, AI-enabled antibody developer.
iBio, Inc. (IBIO) announced its first Statement of Work under a Master Services Agreement with ATB Therapeutics to produce bioengineered antibody-toxin fusion proteins known as atbodies™. This collaboration aims to aid in developing treatments for cancers. Both companies expressed optimism regarding the partnership's potential to speed up the manufacturing process for clinical trials. iBio leverages its FastPharming® System to enhance production capabilities, reinforcing its position as a leader in plant-based biologics.
iBio Announces Patent Issuance for Antifibrotic Development
iBio has secured U.S. Patent No. 10,844,392, enhancing its FastPharming® System. This patent is crucial for the production of endostatin-derived peptides, supporting the development of IBIO-100 for fibrotic disorders like systemic scleroderma and idiopathic pulmonary fibrosis. The patent includes 19 claims and expires in June 2036. iBio plans to initiate IND-enabling studies for IBIO-100 in 2021, expanding its therapeutic offerings and intellectual property portfolio in the biotechnology field.
iBio, a biotech innovator, announced its financial results for Q1 FY2021, reporting revenues of approximately $0.4 million, a 280% increase from the same period last year. The company’s net loss was about $7.5 million, or $0.05 per share. R&D expenses rose to $1.8 million, primarily due to increased laboratory supplies. iBio's revenue backlog stands at $2.4 million, and cash and investments totaled $83.5 million. The company highlights its partnerships and ongoing development of COVID-19 therapeutics as part of its growth strategy.
On November 12, 2020, iBio (NYSE: IBIO) announced its participation in Alliance Global Partners' Virtual Healthcare Symposium on November 19, 2020. The company will engage in one-on-one meetings with institutional investors and join a panel discussing the future of COVID-19 treatments. iBio is recognized for its plant-based biologics manufacturing and is advancing treatments like IBIO-100 for fibrotic diseases. The panel, led by Jim Molloy, will address upcoming diagnostics and therapies following major vaccine developments.
iBio, Inc. (NYSEA:IBIO) announced it will release its fiscal 2021 Q1 financial results on November 16, 2020, after market close. The management will host a conference call at 4:30 p.m. ET to discuss the results and provide corporate updates. Investors can access the live and archived webcast on www.ibioinc.com in the Investors section. iBio specializes in plant-based biologics manufacturing, using its patented FastPharming System to produce monoclonal antibodies, vaccines, and other proteins.
iBio Appoints New COO
iBio has appointed Randy J. Maddux as Chief Operating Officer, effective December 1, 2020. With over 20 years of experience in biologics drug development and manufacturing, Maddux previously held leadership roles at Aptevo Therapeutics and GlaxoSmithKline, where he managed significant manufacturing sites. His expertise in biologics is expected to benefit iBio as it expands its pipeline and contract development and manufacturing services. The company focuses on plant-based biologics through its FastPharming system and has promising products in the pipeline, including treatments for fibrotic diseases.
iBio has appointed Gary Sender to its Board of Directors effective October 14, 2020. He will chair the Audit Committee and join the Compensation Committee. Sender brings over 25 years of financial leadership experience from the pharmaceutical and biotech sectors, currently serving as CFO of Nabriva Therapeutics. He has previously held senior roles at Synergy Pharmaceuticals and Shire Plc.
Sender's expertise is expected to enhance iBio's strategic growth, particularly with its FastPharming® System and proprietary technologies.
iBio has appointed Dr. Alexandra Kropotova as a new Board member, effective October 14, 2020. She will also join the newly formed Science & Technology Committee, chaired by Dr. Philip Russell. Dr. Kropotova brings over 20 years of experience in biopharmaceuticals, having held leadership roles at Teva Pharmaceuticals, Sanofi, and Pfizer. Her expertise includes global clinical development and translational medicine. CEO Tom Isett expressed confidence in her contributions to advancing iBio's initiatives in pulmonology, oncology, and fibrotic diseases.
iBio, a biotech company, has appointed Dr. Linda Armstrong to its Board of Directors and the newly established Science & Technology Committee. Dr. Armstrong brings over 20 years of expertise in respiratory diseases, having previously served as Global Head of Respiratory Development at Novartis. Her experience in biologics development is expected to enhance iBio's respiratory disease portfolio, including COVID-19 therapeutic candidates and IBIO-100 for idiopathic pulmonary fibrosis. iBio aims to leverage her insights to advance its product development initiatives.
iBio, a biotech innovator, reported record revenues of over $1.1 million in Q4 and total revenues of approximately $1.6 million for the fiscal year ended June 30, 2020. This reflects a decrease from $2.0 million in FY 2019, mainly due to timing in service revenues. However, revenue from third-party customers increased by 118%. Operating expenses fell to $15.6 million from $17.8 million, while net loss narrowed to $16.4 million or $0.61 per share. iBio's cash position strengthened, increasing to $83.1 million by September 30, 2020.